Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

9 Meters Biopharma Inc (NMTRQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.0001 0.0000    0.00%
27/03 - Closed. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.0001 - 0.0001
Type:  Equity
Market:  United States
Innovate Biopharma 0.0001 0.0000 0.00%

Innovate Biopharma Company Profile

 
Read the 9 Meters Biopharma Inc company profile to learn more about the business and the management team. View 9 Meters Biopharma Inc facts about employee data, company products and services, and contact information.
IndustryInvestment Holding Companies
SectorFinancial
Employees

10

Equity Type

ORD

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Contact Information

Address 4509 Creedmoor Road Suite 201
Raleigh, 27612
United States
Phone 919 275 1933
Fax -

Top Executives

Name Age Since Title
Lorin K. Johnson 70 2018 Independent Director
Mark A. Sirgo 69 2020 Independent Chairman
Maureen Leonard - 2020 Member of Scientific Advisory Board
Mark Pimentel - 2020 Member of Scientific Advisory Board
Russel Cohen - 2020 Member of Scientific Advisory Board
Charles Randall - 2020 Member of Scientific Advisory Board
Benjamin Lebwohl - 2020 Member of Scientific Advisory Board
Samantha Ventimiglia 51 2021 Independent Director
Z. Myron Falchuk - 2020 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NMTRQ Price Commentary

Write your thoughts about 9 Meters Biopharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Selim Yucel
Selim Yucel Aug 14, 2021 13:26
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Invester of NMTR will be sick; if continue like that...🤦‍♂️
Boori khan
Boori khan Jan 20, 2021 10:40
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This company have lot of potential.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email